Evidence map›Paper›PMID 38391908›Full record

ArticleCells2024

Vasoactive Intestinal Peptide Receptor, CRTH2, Antagonist Treatment Improves Eosinophil and Mast Cell-Mediated Esophageal Remodeling and Motility Dysfunction in Eosinophilic Esophagitis.

Chandra Sekhar Yadavalli, Sathisha Upparahalli Venkateshaiah, Alok K Verma, Chandrasekhar Kathera, Pearce S Duncan, Michael Vaezi, Richard J Paul, Anil Mishra

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 1 country.

Chandra Sekhar YadavalliDepartment of Medicine, Section of Pulmonary Diseases, Tulane Eosinophilic Disorder Center, School of Medicine, Tulane University, New Orleans, LA 70112, USA.ORCID 0000-0001-7776-1543
Sathisha Upparahalli VenkateshaiahDepartment of Medicine, Section of Pulmonary Diseases, Tulane Eosinophilic Disorder Center, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Alok K VermaDivision of Gastroenterology, Cincinnati Childrens Medical Center, Cincinnati, OH 45229, USA.
Chandrasekhar KatheraDepartment of Medicine, Section of Pulmonary Diseases, Tulane Eosinophilic Disorder Center, School of Medicine, Tulane University, New Orleans, LA 70112, USA.ORCID 0000-0002-6900-9447
Pearce S DuncanDivision of Gastroenterology, School of Medicine, Tulane University, New Orleans, LA 70118, USA.
Michael VaeziDivision of Gastroenterology, Vanderbilt University Medical Center, Nashville, TN 37232, USA.
Richard J PaulDivision of Physiology, Cincinnati University, Cincinnati, OH 45220, USA.
Anil MishraDepartment of Medicine, Section of Pulmonary Diseases, Tulane Eosinophilic Disorder Center, School of Medicine, Tulane University, New Orleans, LA 70112, USA.
Tulane University · USCincinnati Children's Hospital Medical Center · USUniversity of Cincinnati · USVanderbilt University Medical Center · US

Funding

Role of IL-15 in the Pathogensis of Eosinophilic EsophagitisR01AI080581 · NIAID · TULANE UNIVERSITY OF LOUISIANA · PI MISHRA, ANIL · 2009 to 2023
$4.9M
NIAID NIH HHS R01 AI080581NIH HHS RO1 AI080581
6 · The paper itself

Abstract

BACKGROUND AND

aimsUltrasonography has shown that eosinophils accumulate in each segment of the esophageal mucosa in human EoE, ultimately promoting esophageal motility dysfunction; however, no mechanistic evidence explains how or why this accumulation occurs.

methodsQuantitative PCR, ELISA, flow cytometry, immunostaining, and immunofluorescence analyses were performed using antibodies specific to the related antigens and receptors.

resultsIn deep esophageal biopsies of EoE patients, eosinophils and mast cells accumulate adjacent to nerve cell-derived VIP in each esophageal segment.

conclusionsCRTH2 antagonist treatment is a novel therapeutic strategy for inflammatory cell-induced esophageal motility dysfunction in IL-13-induced chronic experimental EoE.

Indexed as

EnteritisEosinophiliaEosinophilic EsophagitisGastritisAnimalsEosinophilsHumansInterleukin-13Mast CellsMiceReceptors, Vasoactive Intestinal PeptideVasoactive Intestinal PeptideInterleukin-13Receptors, Vasoactive Intestinal PeptideVasoactive Intestinal PeptideCRTH2EoEeosinophilsesophagusmast cellsmotility

Identifiers

PMID38391908
PMCPMC10886969
OpenAlexW4391574309

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.